Troy Bio Overview
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Troy Bio General Information
Description
Developer of an enzyme replacement therapy delivery platform designed for the treatment of orphan diseases. The company's platform combines transferrin receptor1 antibodies with therapeutic enzymes, increasing their bioavailability in the central nervous system and muscles, enabling the healthcare industry to treat regimen for rare hereditary diseases such as Hunter syndrome and Pompe disease.
Contact Information
Website
www.troy-bio.ruCorporate Office
- 1, room 2-037
- Federal Territory Sirius, Triumfalny proez
- Krasnodar Krai, 354340
- Russia
Corporate Office
- 1, room 2-037
- Federal Territory Sirius, Triumfalny proez
- Krasnodar Krai, 354340
- Russia
Troy Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jul-2024 | Completed | Startup |
Troy Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Unicorn Capital Partners | Venture Capital | Minority |
Troy Bio FAQs
-
Where is Troy Bio headquartered?
Troy Bio is headquartered in Krasnodar Krai, Russia.
-
What industry is Troy Bio in?
Troy Bio’s primary industry is Therapeutic Devices.
-
Is Troy Bio a private or public company?
Troy Bio is a Private company.
-
What is Troy Bio’s current revenue?
The current revenue for Troy Bio is .
-
Who are Troy Bio’s investors?
Unicorn Capital Partners has invested in Troy Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process